Boehringer Ingelheim’s Iclepertin Fails to Meet Phase III Study Endpoints
German giant Boehringer Ingelheim has disclosed negative top-line results from the Phase III CONNEX study...
Telix Pharmaceuticals’ TLX591-CDx Approved in Europe via Decentralized Procedure
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that the marketing filing in Europe via...
NMPA Implements Regulatory Reforms for Drug and Medical Device Industries
The National Medical Products Administration (NMPA) has released a notification regarding the implementation of the...
Daiichi Sankyo Acquires Gatipotuzumab IP Rights for $132.5M
Japan-based Daiichi Sankyo Company, Ltd (TYO: 4568) has announced an investment of USD 132.5 million...
NHSA Pushes for Real-Time Settlement Reform in Basic Medical Insurance
The National Healthcare Security Administration (NHSA) has released a notification to promote the real-time settlement...
a16z Bio + Health Launches Biotech Ecosystem Venture Fund
Andreessen Horowitz (a16z) Bio + Health has announced the establishment of the Biotech Ecosystem Venture...
Impact Therapeutics’ Senaparib Cleared by NMPA for Ovarian Cancer Therapy
China-based Impact Therapeutics has announced receiving marketing clearance from the National Medical Products Administration (NMPA)...
Siemens Lays Foundation for New Medical Equipment Base in Shenzhen
Siemens (Shenzhen) Magnetic Resonance Co., Ltd., a wholly-owned subsidiary of Siemens Ltd., China, has officially...
Fujian Haixi Pharmaceuticals Files for Hong Kong IPO
China-based Fujian Haixi Pharmaceuticals Co., Ltd., a commercial-stage innovative pharmaceutical company, has made an initial...
SciClone and Menarini Submit NDA for Vaborem in China
China-based SciClone Pharmaceuticals Inc and its Italy-based strategic partner Menarini have announced the submission of...
Servier and Google Cloud Extend Partnership to Advance AI in Drug Development
France-based Servier Group and US technology firm Google Cloud have announced an expansion to their...
Cathay Biotech Plans $901M Private Placement to Boost Bio-Based Materials
Shanghai-based Cathay Biotech Inc. (SHA: 688065) has announced plans to raise RMB 6.6 billion (USD...
Simcere Licenses Fermion’s AI-Enabled Painkiller FZ002-037
China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced a licensing agreement with compatriot firm...
Boston Scientific’s FARAPULSE and WATCHMAN FLX Studies Show Positive Results
US major Boston Scientific Corporation (NYSE: BSX) has announced the presentation of positive results from...
Asieris’ USP1 Inhibitor APL-2302 Cleared for Clinical Trials
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced receiving clinical clearance from the...
Zhejiang Huahai’s HB0056 Approved for US Phase I Asthma Trial
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval from...
Hengrui’s HER2-Targeted ADC and Antibody Drug Combo Approved for Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical trial approval from...
CSPC’s SYS 6043 Receives FDA Approval for Clinical Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its in-house developed SYS 6043...
Innovent’s Limertinib Wins NMPA Approval for NSCLC Treatment
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that it has received New Drug Application...
ConjuStar Completes $15 Million Pre-A+ Financing Round
ConjuStar, a clinical-stage biotechnology company based in Tianjin, China, has announced the completion of a...